IW 3718

Drug Profile

IW 3718

Alternative Names: IW-3718

Latest Information Update: 25 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ironwood Pharmaceuticals
  • Class Digestion aids
  • Mechanism of Action Bile acid binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Gastro-oesophageal reflux

Most Recent Events

  • 03 Aug 2017 Ironwood plans a phase III trial for Gastro-oesophageal reflux in second half of 2018
  • 20 Jul 2017 Ironwood Pharmaceuticals has patent protection and pending patents for IW 3718
  • 20 Jul 2017 Efficacy data from a phase IIb trial in Gastro-oesophageal reflux, which met its primary endpoint, released by Ironwood Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top